Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Publication date: Jul 14, 2023

A range of preclinical and clinical studies suggest therapeutic potential in multiple indications, including levodopa-induced dyskinesia, neuropathic pain, seizures, major depressive disorder, and suicidal ideation. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety, depression and several other CNS disorders. In clinical and nonclinical testing completed to date, AV-101 has demonstrated good oral bioavailability and an excellent pharmacokinetic (PK) profile. These forward-looking statements involve known and unknown risks that are difficult to predict and include all matters that are not historical facts. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. The study demonstrated that AV-101 significantly (p = 0. 01) reduced LID without affecting the timing, extent, or duration of the therapeutic benefits of L-Dopa. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Vistagen and its management, are inherently uncertain.

Concepts Keywords
Biopharmaceutical Av
Canada Clinical
July Companys
Parkinsons Dyskinesia
Including
Levodopa
Looking
Nmdar
Oral
Patent
Related
Risks
Statements
Treatment
Vistagen

Semantics

Type Source Name
drug DRUGBANK AV-101
disease MESH Dyskinesia
drug DRUGBANK Levodopa
drug DRUGBANK Gold
drug DRUGBANK Amantadine
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Glycine
disease MESH complications
drug DRUGBANK Kynurenic Acid
drug DRUGBANK Ketamine
disease MESH neuropathic pain
disease MESH seizures
disease MESH major depressive disorder
disease MESH suicidal ideation
disease MESH neurological disorders
drug DRUGBANK PH94B
drug DRUGBANK Coenzyme M

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *